Skip to main navigation
Rhythm Pharmaceuticals, Inc. Logo
  • Careers
  • Investors & Media
  • International
  • Search
  • Science
    • MC4R Pathway
    • Clinical Focus
    • Research & Development
  • Clinical Trials
  • Patients
    • Disease Focus
  • Product
  • About
    • Our People
    • Leadership
  • Science
    • MC4R Pathway
    • Clinical Focus
    • Research & Development
  • Clinical Trials
  • Patients
    • Disease Focus
  • Product
  • About
    • Our People
    • Leadership
  • Careers
  • Investors & Media
  • International
  • Search
  • Overview
  • Events & Presentations
  • Stock
  • Corporate Governance
  • Financials
    • SEC Filings
    • Quarterly Results
    • Annual Reports
  • News
  • IR Resources
    • Investor FAQs
    • Email Alerts
    • Contact Us

News

February 23, 2022
Rhythm Pharmaceuticals Announces Promotions within its Executive Leadership Team
February 22, 2022
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on Tuesday, March 1, 2022
February 16, 2022
Rhythm Pharmaceuticals Announces Positive Interim Data from Long-term Extension Study of Setmelanotide in Bardet-Biedl Syndrome (BBS)
February 8, 2022
Rhythm Pharmaceuticals to Host Virtual Bardet-Biedl Syndrome (BBS) Event on February 16
January 13, 2022
Rhythm Pharmaceuticals Announces First Patients Dosed in DAYBREAK and Weekly Trials Evaluating Setmelanotide for Rare Genetic Diseases of Obesity
December 6, 2021
Rhythm Pharmaceuticals and RareStone Ltd. Announce Exclusive Licensing Agreement for the Development and Commercialization of IMCIVREE (setmelanotide) in China
November 15, 2021
Rhythm Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) for Patients with Bardet-Biedl Syndrome and Alström Syndrome
November 9, 2021
Rhythm Pharmaceuticals to Present at Stifel 2021 Virtual Healthcare Conference
November 2, 2021
Rhythm Pharmaceuticals Reports Third Quarter 2021 Financial Results
November 1, 2021
Rhythm Pharmaceuticals Presents First-ever Data Showing Improvements in Health-related Quality of Life for Patients Living with Bardet-Biedl Syndrome at ObesityWeek® 2021
  • First page «
  • Previous page ‹
  • …
  • Page 16
  • Page 17
  • Current page 18
  • Page 19
  • Page 20
  • …
  • Next page ›
  • Last page »
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • California Compliance

Rhythm Pharmaceuticals, Inc.
222 Berkeley Street, 12th Floor
Boston, MA 02116

This website is intended only for residents of the United States.

© 2026, Rhythm Pharmaceuticals, Inc. All Rights Reserved. Rhythm, IMCIVREE, GOLD Academy, LEAD for Rare Obesity, Uncovering Rare Obesity, and their logos are trademarks of Rhythm Pharmaceuticals, Inc.

US-RHY-2400016 05/2024